Lisuride

Oral
Parkinson's disease

Oral
Suppression of lactation

Oral
Acromegaly, Hyperprolactinaemia-associated disorders

Should be taken with food. Always take w/ a meal or snack.

Serious peripheral arterial disorders and coronary insufficiency. Concomitant use w/ phenylpropanolamine.

Patient w/ past or present psychosis. Avoid abrupt withdrawal. Pregnancy and lactation.

Nausea, vomiting, dry mouth, obstipation, peripheral oedema, sweating, hallucination, anxiety, confusion, nightmares, insomnia, decreased appetite, dyskinesia, somnolence, vertigo, headache, dystonia, myoclonus, orthostatic hypotension, cold extremities, erythromelalgia, palpitation, dyspnoea.

This drug may cause somnolence, if affected, do not drive or operate machinery.

Monitor regularly for development of impulse control disorders.

Symptoms: Severe dopamine-agonistic reactions e.g. nausea, vomiting and vertigo. Management: Metoclopramide oral drops (or domperidone in parkinsonism) may be given as antidote for mild cases. Severe cases may be treated w/ IM sulpiride 100 mg.

Enhanced sedative effect w/ drugs that have CNS depressant effects (e.g. benzodiazepines, antipsychotics). Mutual antagonistic effect w/ antipsychotic neuroleptics (except clozapine). Risk of vasoconstriction and/or hypertensive crisis w/ sympathomimetics (alpha and indirect) and vasoconstrictive ergot alkaloids. Increased risk of neuropsychic disorders w/ anticholinergic antiparkinsonians. Effects may be attenuated by neuroleptics and other dopamine antagonists.
Potentially Fatal: Risk of vasoconstriction and/or hypertensive crises w/ phenylpropanolamine.

Enhanced sedative effect w/ alcohol.

Description:
Mechanism of Action: Lisuride directly stimulates postsynaptic dopamine receptors, thereby improving or eliminating the reduced locomotion, rigor and tremor. It also suppresses the normal production and flow of milk and improves pathological states of the mammary gland.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: 1.1-1.3 hr.
Distribution: Widely distributed into the body. Volume of distribution: 2.3 L/kg. Plasma protein binding: 66%.
Metabolism: Undergoes hepatic metabolism, mainly via oxidation pathways including N'-desalkylation of ethyl groups, hydroxylation of the benzene ring, mono-oxygenation and oxidation of double bonds.
Excretion: Via urine, as metabolites. Plasma elimination half-life: 10 hr.

Source: National Center for Biotechnology Information. PubChem Database. Lisuride, CID=28864, https://pubchem.ncbi.nlm.nih.gov/compound/Lisuride (accessed on Jan. 22, 2020)

Store below 30°C. Protect from light.

Antiparkinsonian Drugs / Other Drugs Affecting Hormonal Regulation

N02CA07 - lisuride ; Belongs to the class of ergot alkaloids preparations. Used to relieve migraine.
G02CB02 - lisuride ; Belongs to the class of prolactine inhibitors. Used to suppress lactation.

Bayer New Zealand Limited. Dopergin Tablet data sheet 11 April 2013. Medsafe. http://www.medsafe.govt.nz/. Accessed 07/04/2016.

Buckingham R (ed). Lisuride Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/04/2016.